Market Currents
An FDA panel has voted 12-1 against expanded use of Amgen's (AMGN -1.2%) Xgeva for prostate...
-
Wednesday, February 8, 2012, 12:16 PM ETAn FDA panel has voted 12-1 against expanded use of Amgen's (AMGN -1.2%) Xgeva for prostate cancer bone met prevention, according to a Bloomberg report. (pdf)
Other date
Latest Articles
